公开(公告)号：EP4368199A3

公开(公告)日：2024-08-21

申请号：EP23205007.0

申请日：2018-02-28

申请人： GENENTECH, INC. ,  F. Hoffmann-La Roche AG

发明人： BENYUNES, Mark, C. ,  ROSS, Graham Alexander

IPC分类号： C07K16/32 ,  A61P35/00 ,  A61K9/00 ,  A61K45/06 ,  A61K39/395 ,  A61K31/337 ,  A61K31/513 ,  A61K31/555 ,  A61K31/675 ,  A61K31/704 ,  A61K39/00

CPC分类号： A61P35/00 ,  A61K2039/50720130101 ,  C07K16/32 ,  A61K39/39558 ,  A61K31/513 ,  A61K31/555 ,  A61K31/675 ,  A61K31/704 ,  A61K31/337 ,  A61K45/06

摘要： Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

公开(公告)号：EP4410375A2

公开(公告)日：2024-08-07

申请号：EP24179691.1

申请日：2019-09-11

申请人： iTeos Belgium SA

发明人： CROSIGNANI, Stefano ,  DICKINSON, Paul ,  DE MATAS, Marcel ,  HOUTHUYS, Erica Joke Katelijne Heleen ,  MARILLIER, Reece Gerrad ,  MARTINOLI, Chiara ,  DE HENAU, Olivier ,  DRIESSENS, Gregory

IPC分类号： A61P35/00

CPC分类号： A61K9/4858 ,  A61K9/4866 ,  A61K31/337 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K45/06 ,  A61P35/00 ,  C07D513/14 ,  A61K31/5377 ,  A61K33/243 ,  A61K39/3955 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/7620130101

摘要： The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors

Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhibitor of Formula (I) and a lipid carrier such as lauroyl macrogol-32 glycerides, D-α-tocopherol-polyethylene glycol-1000 succinate or a mixture thereof. The pharmaceutical composition of the invention is particularly useful for oral dosing in the treatment of cancers.
The present invention also relates to a combination comprising an A2A receptor inhibitor of Formula (I) and an anticancer agent. The anticancer agent is for example an immunotherapeutic agent, such as a checkpoint inhibitor. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination. Additionally, the combination of the invention is particularly useful for the treatment and/or prevention of cancers.

公开(公告)号：EP4408986A1

公开(公告)日：2024-08-07

申请号：EP22873940.5

申请日：2022-09-27

申请人： Beam Therapeutics Inc. ,  Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Zoulim, Fabien ,  Martinez, Maria, Guadalupe ,  Testoni, Barbara

发明人： SMEKALOVA, Elena ,  BARRERA, Luis ,  ZOULIM, Fabien ,  MARTINEZ, Maria, Guadalupe ,  TESTONI, Barbara

IPC分类号： C12N7/04 ,  A61K31/7125 ,  A61P31/20 ,  C07K14/005 ,  C12N9/22 ,  C12N9/78 ,  C12N15/113 ,  C12N15/90

CPC分类号： A61K31/7125 ,  A61P31/20 ,  C12N9/22 ,  C12N9/78 ,  C12N15/90 ,  A61K31/513 ,  C12N7/00 ,  C12N2730/1012120130101 ,  C12N2730/1016220130101 ,  C12Y305/04004 ,  C12Y305/04005 ,  C12N15/1131 ,  C12N2310/2020170501 ,  C12N2320/1120130101

公开(公告)号：EP3423061B1

公开(公告)日：2024-08-07

申请号：EP17760400.6

申请日：2017-02-28

IPC分类号： A61K31/513 ,  A61K31/4412 ,  A61K31/675 ,  A61K31/685 ,  A61P35/00 ,  A61K31/44

CPC分类号： A61K31/513 ,  A61K31/44 ,  A61K31/675 ,  A61K31/685 ,  A61P35/00

公开(公告)号：EP4125881B1

公开(公告)日：2024-07-24

申请号：EP21715306.3

申请日：2021-03-22

IPC分类号： A61K31/4178 ,  A61K31/573 ,  A61K31/706 ,  A61K38/21 ,  A61K45/06 ,  A61P31/14

CPC分类号： A61K31/4178 ,  A61K31/573 ,  A61K31/706 ,  A61K38/215 ,  A61K45/06 ,  A61P31/14 ,  A61K31/16 ,  A61K31/7056 ,  A61K31/513

公开(公告)号：EP3873460B1

公开(公告)日：2024-06-12

申请号：EP19805046.0

申请日：2019-10-28

IPC分类号： A61K31/40 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/513 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K45/06 ,  A61P35/00 ,  A61K31/496 ,  A61K31/454 ,  A61K31/4439 ,  A61K31/40 ,  A61K31/513 ,  A61P35/02 ,  Y02A50/30

公开(公告)号：EP3890737B1

公开(公告)日：2024-06-05

申请号：EP19821175.7

申请日：2019-12-06

IPC分类号： A61K31/4545 ,  A61K31/496 ,  A61K31/513 ,  A61K31/5377 ,  A61P3/04 ,  A61P5/48 ,  A61P21/00 ,  A61P35/00

CPC分类号： A61K31/4545 ,  A61K31/513 ,  A61K31/496 ,  A61K31/5377 ,  A61P3/04 ,  A61P5/48 ,  A61P21/00 ,  A61P35/00

公开(公告)号：EP3046564B1

公开(公告)日：2024-05-22

申请号：EP14766481.7

申请日：2014-09-16

IPC分类号： A61K31/713 ,  A61K31/7105 ,  A61P25/08 ,  A61K31/513

CPC分类号： A61K31/381 ,  A61K31/513 ,  A61P25/08 ,  A61K31/713 ,  A61K31/7105

公开(公告)号：EP4306129A3

公开(公告)日：2024-04-17

申请号：EP23213674.7

申请日：2021-02-26

申请人： Verona Pharma PLC

发明人： SPARGO, Peter Lionel ,  HAYWOOD, Phillip Andrew ,  FRENCH, Edward James

IPC分类号： A61K9/10 ,  A61P11/00 ,  A61K31/40 ,  A61K31/519 ,  A61K47/14

CPC分类号： A61P11/00 ,  A61K31/40 ,  A61K9/0078 ,  A61K9/10 ,  A61K47/14 ,  A61K31/513

摘要： The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) ensifentrine particles; (ii) glycopyrrolate; and (iii) a diluent, which diluent comprises water, wherein: the glycopyrrolate is dissolved in the diluent; the concentration of glycopyrrolate is less than or equal to 5.0 mg/mL; and the pH of the liquid pharmaceutical composition is from 3.0 to 6.0. The invention also relates to a nebuliser comprising the liquid pharmaceutical composition.

公开(公告)号：EP3405193A1

公开(公告)日：2018-11-28

申请号：EP17741744.1

申请日：2017-01-19

申请人： Achromaz Pte. Ltd.

发明人： CHEETHAM, Peter Samuel James ,  LANGWALLNER, Christoph ,  LANGWALLNER, Margit ,  TAN, Wen Jue Amelia

IPC分类号： A61K31/425 ,  A61K31/351 ,  A61K31/522 ,  A61K31/39 ,  A61K31/375 ,  A61K31/4412 ,  A61K31/536 ,  A61K31/192 ,  A61K31/122 ,  A61K31/343 ,  A61K31/216 ,  A61K31/166 ,  A61K31/12 ,  A61K31/245 ,  A61K31/194 ,  A61K31/616 ,  A61K31/4035 ,  A61K31/513 ,  A61Q19/02 ,  A61Q19/08

CPC分类号： A61K31/12 ,  A61K8/49 ,  A61K8/4953 ,  A61K8/4973 ,  A61K8/498 ,  A61K8/55 ,  A61K31/122 ,  A61K31/166 ,  A61K31/192 ,  A61K31/194 ,  A61K31/215 ,  A61K31/216 ,  A61K31/222 ,  A61K31/341 ,  A61K31/343 ,  A61K31/351 ,  A61K31/4035 ,  A61K31/425 ,  A61K31/4412 ,  A61K31/513 ,  A61K31/52 ,  A61K31/522 ,  A61K31/536 ,  A61K31/54 ,  A61K31/708 ,  A61Q19/02 ,  A61Q19/08

摘要： The present invention relates to cosmetic or personal care compositions comprising two or more compounds, each compound containing an allylic or partially allylic carbonylsubstructure having the following structure I:wherein Y is a second substructure immediately adjacent to the allylic or partially allyliccarbonyl substructure and is selected from one of the following groups consisting of (i)hydroxyl-based group including -OH or -C(=)-(OH); (ii) carbonyl-based group including -C(=)-C (=O)-CH3; (iii) ether group, -O-; (iv) sultam group, -N(H)-S(=O)2-; (v) lactam group,-N(H)-C(=O)-; (vi) apolar group including cyclic structures based on menthol orcarotenoids; (vii) secondary aldimine containing group including -N(H)-C(NH2)=N- or -N(H)-C(H)=N-; (viii) amine group, -NH2; (ix) secondary amine-based group, -N(H)-; and(x) amide-based group including -N(H)-C(=O)- or -N(H)-C(=O)-N(H)-, their derivatives,isomers, salts and/or combination thereof; and a cosmetically acceptable vehicle.